<h4>Background</h4>Capivasertib is recommended, plus fulvestrant, for hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with PIK3CA/AKT1/PTEN alterations and is under development for further breast and prostate cancer indications. This evidence concerns the gene PTEN and prostate carcinoma.